Theses›Healthcare & bio›Biophotonics

Biophotonics

In biophotonics the venture-differentiated layer is the photonic-IC / source / detector silicon inside the instrument, not the clinical device; value migrates forward to the regulated device and assay incumbent, so capture is mostly public/incumbent through 2029

  • Bear
  • Closing
  • $1.6B by 2035

The callThe chip is the hard part and the money moves forward to whoever owns the cleared device and the assay, so the only private opening is a device that owns its chip.

D1D2R1R2C1foragainst D1D2R1R2C1foragainst
Fig. 1The balance. Drivers and catalysts against restraints, each block sized by its weight; catalysts hang dashed because they have not happened yet, sized by their odds. It tips toward the restraints.
  1. D1Testing moves from the central lab to the home and bedside, and bench-sized analysers built for throughput per lab cannot follow the patient.
  2. D2The incumbents do not make the chip, and a photonic chip can read a lab-grade assay from a drop of blood, run many markers and be cheap enough to discard.
  3. R1Value moves forward: companies selling chips into instrument makers get bought or squeezed before they hold value, and the component layer is 0-for-N at venture scale.
  4. R2The integrated device route costs $10-100M to get through a predicate and a clinical study, and SiPhox, on $27M raised, has not filed.
  5. C1SiPhox Home gets FDA clearance, the first at-home biophotonic diagnostic cleared as a consumer device, opening about $700M for devices of that shape.2026
Rests onthe beliefs underneath
Supported by · confidence
What would prove itdated tests, open and resolved
20272028today123predictionswatch 20272028today123predictionswatch
Fig. 2Each ring is a dated test: dashed while open, struck through when overdue, ticked or crossed once resolved.
  1. 1Whether SiPhox files for clearance.Dec 2026 · open
  2. 2At least one European PIC-platform biosensor company raises a Series A of >=€5M by end-2027, demonstrating that the chip-layer supplier model captures independent venture-scale value rather than being absorbed into an assay-maker.Dec 2027 · open
  3. 3Medical-grade photonic bio chipsets reach the market; that starts the incumbents' clock.Dec 2027 · open
Expressionslisted, private, technologies
Private · 6 private companies.

ILOF (Intelligent Lab On Fiber Limited) · SiPhox Health · iLoF (Intelligent Lab on Fiber) · Refined Diagnostics (Refined Laser Systems) · GlucoSet · ArcanaBio

25 more private companies tracked, not shown

Technologies
Who has already bet on itprivate rounds, from public sources

$41M raised by 5 companies, $6M of it in the last three years. Wave building: Money is arriving: recent rounds and tier-1 funds are in, but no runaway leader yet.

Backed by a top-tier venture firm: SiPhox Health. Backed by a strategic investor: SiPhox Health, iLoF (Intelligent Lab on Fiber).